Faruqi & Faruqi, LLP Announces Investigation of Pharmaceutical Product Development Inc. (PPDI)
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Pharmaceutical Product Development Inc. (“PPD” or the “Company”) (NASDAQ: PPDI) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to the Carlyle Group and Hellman & Friedman LP in an all-cash deal valued at about $3.79 billion. Under the terms of the proposed transaction, PPD’s stockholders will receive $33.25 in cash per each share of PPD they own, while according to Yahoo! Finance, at least one financial analyst has set a price target of $38 for PPD.
Whether PPD’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether the proposed transaction undervalues PPD’s shares and by how much this proposed transaction undervalues the Company to the detriment of PPD’s shareholders are the key focus of this investigation.
If you own common stock in PPD and wish to obtain additional information, please visit us at www.faruqilaw.com/PPDI or contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.